## **Anton-Scott Goustin**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4542149/publications.pdf

Version: 2024-02-01

49 papers

5,000 citations

304368 22 h-index 205818 48 g-index

49 all docs

49 docs citations

times ranked

49

3707 citing authors

#	Article	IF	CITATIONS
1	Estrogen distinctly regulates transcription and translation of lncRNAs and pseudogenes in breast cancer cells. Genomics, 2022, 114, 110421.	1.3	5
2	Alzheimer's trials: A cul-de-sac with no end in sight. Advances in Clinical and Experimental Medicine, 2021, 30, 653-654.	0.6	5
3	Gestational Age Dependence of the Maternal Circulating Long Non-Coding RNA Transcriptome During Normal Pregnancy Highlights Antisense and Pseudogene Transcripts. Frontiers in Genetics, 2021, 12, 760849.	1.1	7
4	A Long Non-coding RNA, LOC157273, Is an Effector Transcript at the Chromosome 8p23.1-PPP1R3B Metabolic Traits and Type 2 Diabetes Risk Locus. Frontiers in Genetics, 2020, 11, 615.	1.1	14
5	The Growth-Arrest-Specific (GAS)-5 Long Non-Coding RNA: A Fascinating IncRNA Widely Expressed in Cancers. Non-coding RNA, 2019, 5, 46.	1.3	54
6	Primate-specific oestrogen-responsive long non-coding RNAs regulate proliferation and viability of human breast cancer cells. Open Biology, 2016, 6, 150262.	1.5	10
7	Ahsg-fetuin blocks the metabolic arm of insulin action through its interaction with the 95-kD $\hat{l}^2$ -subunit of the insulin receptor. Cellular Signalling, 2013, 25, 981-988.	1.7	43
8	The "thrifty―gene encoding Ahsg/Fetuin-A meets the insulin receptor: Insights into the mechanism of insulin resistance. Cellular Signalling, 2011, 23, 980-990.	1.7	77
9	Reactivation of p53 by Novel MDM2 Inhibitors: Implications for Pancreatic Cancer Therapy. Current Cancer Drug Targets, 2010, 10, 319-331.	0.8	37
10	SMI of Bcl-2 TW-37 is active across a spectrum of B-cell tumors irrespective of their proliferative and differentiation status. Journal of Hematology and Oncology, 2009, 2, 8.	6.9	26
11	Small-Molecule Inhibitors of Bcl-2 Family Proteins as Therapeutic Agents in Cancer. Recent Patents on Anti-Cancer Drug Discovery, 2008, 3, 20-30.	0.8	26
12	Preclinical Studies of TW-37, a New Nonpeptidic Small-Molecule Inhibitor of Bcl-2, in Diffuse Large Cell Lymphoma Xenograft Model Reveal Drug Action on Both Bcl-2 and Mcl-1. Clinical Cancer Research, 2007, 13, 2226-2235.	3.2	147
13	Superior Anti-Tumor Activity of the CD19-Directed Immunotoxin, SAR3419 to Rituximab in Non-Hodgkin's Xenograft Animal Models: Preclinical Evaluation Blood, 2007, 110, 2339-2339.	0.6	10
14	Surface Plasmon Resonance Study of Apoptotic Regulators Bcl-2, Bcl-w, Bcl-XL, and Mcl-1 Indicate That the Preclinical Small Molecule Inhibitor (SMI) TW-37 Binds to the Hydrophobic Groove Competitively with tBid To Form a Heterodimer Which Cannot Be Disrupted by 200-Fold Molar Excess of TW-37  Blood, 2007, 110, 1606-1606.	0.6	0
15	Sheep red blood cells armed with anti-CD20 single-chain variable fragments (scFvs) fused to a glycosylphosphatidylinositol (GPI) anchor: a strategy to target CD20-positive tumor cells. Journal of Immunological Methods, 2005, 297, 109-124.	0.6	13
16	Role for Human SIRT2 NAD-Dependent Deacetylase Activity in Control of Mitotic Exit in the Cell Cycle. Molecular and Cellular Biology, 2003, 23, 3173-3185.	1.1	449
17	Improved Insulin Sensitivity and Resistance to Weight Gain in Mice Null for the Ahsg Gene. Diabetes, 2002, 51, 2450-2458.	0.3	320
18	Genetic Mapping and Functional Studies of a Natural Inhibitor of the Insulin Receptor Tyrosine Kinase: The Mouse Ortholog of Humanl±2-HS Glycoprotein. International Journal of Experimental Diabetes Research, 2000, 1, 249-263.	1.0	15

#	Article	IF	CITATIONS
19	α2-HSG, a specific inhibitor of insulin receptor autophosphorylation, interacts with the insulin receptor. Molecular and Cellular Endocrinology, 2000, 164, 87-98.	1.6	166
20	Genetic Analysis Reveals Ongoing HIV Type 1 Evolution in Infected Human Placental Trophoblast. AIDS Research and Human Retroviruses, 1999, 15, 1673-1683.	0.5	34
21	DNA Sequence Analysis of the Long Terminal Repeat of the C Subtype of Human Immunodeficiency Virus Type 1 from Southern Africa Reveals a Dichotomy between B Subtype and African Subtypes on the Basis of Upstream NF-IL6 Motif. AIDS Research and Human Retroviruses, 1997, 13, 719-724.	0.5	10
22	Sequence of Chemokine Receptor Gene CCR5 in Chimpanzees, a Natural HIV Type 1 Host. AIDS Research and Human Retroviruses, 1997, 13, 1159-1161.	0.5	9
23	Integration of proviral DNA into the PDGF $\hat{l}^2$ -receptor gene in HTLV-I-infected T-cells results in a novel tyrosine kinase product with transforming activity. Oncogene, 1997, 15, 1051-1057.	2.6	14
24	Elevated interferon-alpha in maternal and umbilical cord blood and in the placental trophoblast suggests natural protection against vertical transmission of HIV-1 in a Kenyan cohort. Aids, 1997, 11, 383-5.	1.0	4
25	<b>Sequence Note</b> : Genetic Polymorphism of Envelope V3 Region of HIV Type 1 Subtypes A, C, and D from Nairobi, Kenya. AIDS Research and Human Retroviruses, 1996, 12, 75-78.	0.5	19
26	Recombinant human α2-HS glycoprotein inhibits insulin-stimulated mitogenic pathway without affecting metabolic signalling in Chinese hamster Ovary cells overexpressing the human insulin receptor. Cellular Signalling, 1996, 8, 567-573.	1.7	22
27	Sequence Note: Spread of HIV Type 1 in Slovakia Remains Limited and Is Restricted to Subtype B. AIDS Research and Human Retroviruses, 1996, 12, 1069-1071.	0.5	4
28	Baculoviral Expression of a Natural Inhibitor of the Human Insulin Receptor Tyrosine Kinase. Biochemical and Biophysical Research Communications, 1995, 208, 879-885.	1.0	17
29	Basal and Tat-transactivated expression from the human immunodeficiency virus type 1 long terminal repeat in human placental trophoblast rules out promoter-enhancer activation as the partial block to viral replication. Journal of General Virology, 1994, 75, 1461-1468.	1.3	11
30	Vertical transmission of HIV: detection of proviral DNA in placental trophoblast. Aids, 1994, 8, 129-30.	1.0	3
31	Serum alpha 2-HS-glycoprotein is an inhibitor of the human insulin receptor at the tyrosine kinase level Molecular Endocrinology, 1993, 7, 1445-1455.	3.7	196
32	Absolute quantification of target DNA: a simple competitive PCR for efficient analysis of multiple samples. Nucleic Acids Research, 1993, 21, 2017-2018.	6.5	125
33	Coexpression of the genes for platelet-derived growth factor B-chain receptor and macrophage colony-stimulating factor 1 receptor during monocytic differentiation Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 2481-2485.	3.3	13
34	Plateletâ€derived growth factor and its receptor in blood cell differentiation and neoplasia. European Journal of Haematology, 1990, 45, 127-138.	1.1	11
35	Temporal and spatial pattern of cellular myc oncogene expression during human placental development. Placenta, 1987, 8, 339-345.	0.7	17
36	Transforming growth factor type $\hat{l}^2$ can act as a potent competence factor for AKR-2B cells. Experimental Cell Research, 1987, 172, 293-303.	1.2	11

3

#	Article	IF	CITATIONS
37	Production and auto-induction of transforming growth factor- $\hat{l}_{\pm}$ in human keratinocytes. Nature, 1987, 328, 817-820.	13.7	843
38	Transforming growth factor alpha and beta expression in human colon cancer lines: implications for an autocrine model. Cancer Research, 1987, 47, 4590-4.	0.4	177
39	Induction of c-sis mRNA and activity similar to platelet-derived growth factor by transforming growth factor beta: a proposed model for indirect mitogenesis involving autocrine activity  Proceedings of the National Academy of Sciences of the United States of America, 1986, 83, 2453-2457.	3.3	504
40	Growth factors and cancer. Cancer Research, 1986, 46, 1015-29.	0.4	725
41	Cell-type-specific pattern of myc protooncogene expression in developing human embryos Proceedings of the National Academy of Sciences of the United States of America, 1985, 82, 5050-5054.	3.3	101
42	Coexpression of the sis and myc proto-oncogenes in developing human placenta suggests autocrine control of trophoblast growth. Cell, 1985, 41, 301-312.	13.5	327
43	Mycoplasma Mimicry of Lymphokine Activity in Tâ€Cell Lines. Scandinavian Journal of Immunology, 1985, 21, 593-600.	1.3	11
44	Spatial and temporal pattern of cellular myc oncogene expression in developing human placenta: Implications for embryonic cell proliferation. Cell, 1984, 38, 585-596.	13.5	218
45	Use of proton n.m.r. spectroscopy for detection of 2-acetamido-2-deoxy-d-mannose- and 2-acetamido-2-deoxy-d-mannuronate-containing carbohydrates. Carbohydrate Research, 1983, 119, 258-262.	1.1	11
46	Direct measurement of histone peptide elongation rate in cleaving sea urchin embryos. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1982, 699, 22-27.	2.4	15
47	Elongation of teichuronic acid chains by a wall-membrane preparation from Micrococcus luteus. Journal of Bacteriology, 1982, 150, 649-656.	1.0	11
48	Protein synthesis, polyribosomes, and peptide elongation in early development of Strongylocentrotus purpuratus. Developmental Biology, 1981, 82, 32-40.	0.9	83
49	Two temporal phases for the control of histone gene activity in cleaving sea urchin embryos (S.) Tj ETQq $1\ 1\ 0.75$	843]4 rgB	T / Gyerlock 1